Clinical Trial Update: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the combination of bortezomib and sorafenib tosylate in newly diagnosed acute myeloid leukemia has posted results. The trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia Cutis
• Myeloid Neoplasm
• Myeloid Sarcoma

Drugs mentioned

• Bortezomib (bortezomib)
• Nexavar (sorafenib tosylate) (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Leukemia Cutis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-07-07